Healthcare · NSE: DIVISLAB · BSE: 532488
Divi's Laboratories: how the business works
Divi's Laboratories makes medicine ingredients for drug companies, mostly abroad, earning ₹10,560 crore of revenue in FY26.
Follow Divi's Laboratories
Email me when Divi's Laboratories's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Divi's Laboratories Limited · Hyderabad, Telangana · Founded 1990
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹10,560 cr
- Net profit, FY26
- ₹2,568 cr
- Manufacturing facilities, FY26
- 3
- Incorporated
- 1990
- Promoter holding, 30 Sep 2026
- 51.88%
The short version
Divi's Laboratories in 5 points
1 · What it sells
Divi's Laboratories makes active pharmaceutical ingredients, the chemicals in medicines that do the work, plus intermediates and nutraceutical ingredients, and its FY26 revenue was ₹10,560 crore.
2 · Who pays it
In FY26, customers in Europe paid 61.0% of Divi's revenue, the Americas 13.2%, India 11.0%, the rest of Asia 10.2% and the rest of the world 4.5% (Cityfort calculation).
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Divi's kept ₹23.2 as profit, after a ₹74 crore one-off labour-code charge and including ₹507 crore of other income, while its EBITDA was 31.9% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Divi's reports a single segment, so it does not disclose which business earns its FY26 EBITDA of ₹3,367 crore (Cityfort calculation), though management said on its Q4 FY26 call (23 May 2026) that custom synthesis was 55% of FY26 sales.
5 · The one thing to watch
Inventories rose from ₹3,954 crore on 31 Mar 2026 to ₹5,540 crore on 30 Sep 2026, while operating cash flow was ₹384 crore in H1 FY27 against ₹1,645 crore in H1 FY26.
Sources: From Divi's FY26 annual report, its Q2 FY26, Q3 FY26, Q4 FY26 and Q2 FY27 results filings, and its Q4 FY26 earnings call · checked
Sources (6)
- 36th Annual Report 2025-26 (FY26)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Consolidated financial results Q3 FY26 (XBRL)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- Consolidated financial results Q2 FY27 (XBRL)
- Consolidated financial results Q2 FY26 (XBRL)
01Where the money goes · FY26
Where does ₹100 of Divi's Laboratories' money go?
Divi's Laboratories · FY26
Receipt for every ₹100
| Materials | ₹37.0 |
|---|---|
| Employee costs | ₹13.0 |
| Other running costs | ₹14.3 |
| Depreciation and interest | ₹4.4 |
| One-off labour-code charge | ₹0.7 |
| Income tax | ₹7.4 |
| Kept as profit | ₹23.2 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 results: each line ÷ total money in (revenue of ₹10,560 crore plus ₹507 crore of other income = ₹11,067 crore) × 100.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Sources (5)
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Divi's Laboratories do?
Drug companies, mostly in Europe and the Americas, pay Divi's to make medicine ingredients; materials take the biggest share, and ₹23.2 of every ₹100 that came in was left as profit in FY26.
- In FY26 customers in Europe gave 61.0% of Divi's revenue, the Americas 13.2%, India 11.0%, the rest of Asia 10.2% and the rest of the world 4.5% (Cityfort calculation).
- Of every ₹100 that came in during FY26, ₹37.0 went on materials, ₹14.3 on other running costs and ₹13.0 on staff.
03Who pays it
Who pays Divi's Laboratories?
Customers in Europe
61%
of revenue
Drug companies in Europe: ₹6,446 crore of FY26 revenue, grouped by where products and services are delivered. Switzerland alone was ₹2,611 crore. Shares are Cityfort calculations from the FY26 revenue by region.
Customers in the Americas
13.2%
of revenue
₹1,397 crore in FY26. The US alone was ₹1,092 crore, down from ₹1,306 crore in FY25.
Customers in India
11%
of revenue
₹1,159 crore in FY26, including ₹12 crore of export incentives.
Customers in the rest of Asia
10.2%
of revenue
₹1,079 crore in FY26.
Customers in the rest of the world
4.5%
of revenue
₹479 crore in FY26.
- Customers in Europe61%
- Customers in the Americas13.2%
- Customers in India11%
- Customers in the rest of Asia10.2%
- Customers in the rest of the world4.5%
Customer concentration
Divi's top five customers gave 51% of FY26 standalone sales, up from 49% in FY25 and 37% in FY24; its top five products gave 48%. Divi's does not name its customers or give the largest customer's share.
- Top 5 customers
- 51%
04How it makes money
How does Divi's Laboratories make money?
Sales have grown faster than costs over the past year, and management says margins swing with the mix of custom work and generics.
Revenue rose 35.4% from Q2 FY26 to Q2 FY27, while employee costs rose 25.4%. Materials fell from 39.5% to 32.1% of revenue, and EBITDA (profit before interest, tax and wear-and-tear of assets) rose from 32.7% to 42.6% of revenue (Cityfort calculations). Nilima Prasad Divi said on 1 Aug 2026 that margins should be read by year, as quarters are lumpy.
EBITDA margin, same quarter a year apart (Cityfort calculation)
32.7%42.6%
Q2 FY26 to Q2 FY27
- Divi's makes key starting materials and intermediates in-house, which Dr Kiran S. Divi said in Aug 2026 strengthens supply assurance.
- Large generic ingredients such as naproxen and gabapentin are made in bulk 'campaigns' and stocked, CARE says.
- Drug innovators hire Divi's to make ingredients for their own medicines, under confidentiality agreements.
- Management said custom synthesis was 60% of standalone sales in Q1 FY27, against 53% in Q1 FY26.
- Management said in Aug 2026 that its three units ran at around 85% of capacity.
- EBITDA was 42.6% of revenue in Q2 FY27, against 32.7% in Q2 FY26 (Cityfort calculation).
↺ Step 6 feeds back into step 1.
05The numbers · Consolidated · ₹ crore
How has Divi's Laboratories done?
Revenue
₹10,560 crFY26
Revenue fell from ₹8,960 crore in FY22 to ₹7,768 crore in FY23, then rose to ₹10,560 crore in FY26; Q2 FY27 revenue of ₹3,676 crore was 35.4% above Q2 FY26.
₹ crore
See the numbers
Net profit
₹2,568 crFY26
Net profit rose from ₹1,600 crore in FY24 to ₹2,568 crore in FY26, and Q2 FY27 profit of ₹1,127 crore was 63.6% above Q2 FY26.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹24.3FY26
EBITDA was 31.9% of revenue (₹3,367 crore) in FY26 after the ₹74 crore labour-code charge against 43.3% in FY22, and 32.6% (₹3,441 crore) in FY26 (Cityfort calculation: before the ₹74 crore labour-code charge).
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹218 crFY26
Free cash flow was ₹218 crore in FY26 against ₹1,987 crore in FY23, while spending on plants and equipment rose from ₹473 crore to ₹2,520 crore.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (17)
- Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL)
- 32nd Annual Report 2021-22 (FY22; NSE zip)
- Consolidated financial results Q4 FY23 and FY23 (XBRL)
- 33rd Annual Report 2022-23 (FY23; NSE zip)
- Consolidated financial results Q4 FY24 and FY24 (XBRL)
- 34th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated)
- Consolidated financial results Q4 FY25 and FY25 (XBRL)
- 35th Annual Report 2024-25 (FY25)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- 36th Annual Report 2025-26 (FY26)
- Consolidated financial results Q3 FY25 (XBRL)
- Consolidated financial results Q1 FY26 (XBRL)
- Consolidated financial results Q2 FY26 (XBRL)
- Consolidated financial results Q3 FY26 (XBRL)
- Consolidated financial results Q1 FY27 (XBRL)
- Consolidated financial results Q2 FY27 (XBRL)
- Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release
06Who runs it
Who runs Divi's Laboratories, and did they deliver?
Dr Murali K. Divi
Managing Director · since 1990
Promoter; a director since 12 Oct 1990. Paid ₹100 crore in FY26 (₹88 crore in FY25).
Dr Kiran S. Divi
Whole-time Director and CEO · since 2001
On the board since 10 Aug 2001; re-appointed for five years from 1 Apr 2025; related to Dr Murali K. Divi and Nilima Prasad Divi. Held 20.34% of the shares on 30 Sep 2026.
Nilima Prasad Divi
Whole-time Director (Commercial) · since 2017
On the board since 27 Jun 2017. Presents the financial results on earnings calls. Held 20.34% of the shares on 30 Sep 2026.
N.V. Ramana
Executive Director · since 1994
A director since 1 Oct 1994. His son N.V. Anirudh was named President (Nutraceuticals) from 7 Nov 2025.
Venkatesa Perumallu Pasumarthy
Chief Financial Officer · since 2025
CFO from 1 Aug 2025, after L. Kishore Babu retired.
Dr Ramesh B.V. Nimmagadda
Chairman (independent director) · since 2017
On the board since 27 Jun 2017. The board had 10 directors, 5 of them independent, on 31 Mar 2026.
What they said, and what happened
1 delivered · 1 partly delivered · 3 too early to tell
Said on 6 Aug 2025
Management said total capital spending for FY26 would be "in the range of 2,000 crores".
DeliveredWhat happened
On 7 Nov 2025 management said FY26 capex would be higher than ₹2,000 crore. FY26 spending on plants and equipment was ₹2,520 crore.
Said on 2 Jan 2025
Divi's said Phase I of Unit 3 at Kakinada had an estimated investment of ₹1,200–1,500 crore, with commercial operations from part of Phase I from 1 Jan 2025.
Partly deliveredWhat happened
On 23 May 2026 management said ₹600 crore of the ₹1,500 crore Kakinada plan had been capitalised.
Said on 25 Apr 2024
Divi's said a ₹650–700 crore capacity addition for a long-term supply agreement was "expected to be operational around January, 2027".
Too early to tellWhat happened
On 1 Aug 2026 Dr Kiran S. Divi said the three major capex programmes were nearing completion, with validations going on.
Said on 24 May 2025
Divi's said it expects "meaningful revenue contribution" from its second long-term supply agreement with a global pharma company.
Too early to tellWhat happened
Divi's has not disclosed revenue from either 2025 agreement in the filings checked to 12 Nov 2026.
Said on 23 May 2026
Management said it looks for double-digit revenue growth, as it has historically, and said the same for the year ahead.
Too early to tellWhat happened
H1 FY27 revenue was ₹6,756 crore, 31.8% above H1 FY26's ₹5,125 crore; FY27 ends on 31 Mar 2027.
Sources (18)
- 36th Annual Report 2025-26 (FY26)
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- Board outcome 3 Feb 2025: re-appointment of Dr. Kiran S. Divi as Whole-time Director and CEO for 5 years
- Shareholding pattern as of 30 Sep 2026 (XBRL)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Board outcome 7 Nov 2025: N.V. Anirudh designated President (Nutraceuticals), senior management
- Board outcome 17 May 2025: CFO L. Kishore Babu superannuates, Venkatesa Perumallu Pasumarthy appointed CFO
- Business Responsibility and Sustainability Report 2025-26
- Earnings call transcript Q1 FY26 (call 6 Aug 2025)
- Earnings call transcript Q2 FY26 (call 7 Nov 2025)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- Information about proposed capacity addition (₹650–700 crore, long-term supply agreement)
- Signing of a second long-term manufacturing and supply agreement with a global pharma company (advanced intermediates)
- Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release
- Consolidated financial results Q2 FY27 (XBRL)
- Consolidated financial results Q2 FY26 (XBRL)
07What could go wrong
What could go wrong for Divi's Laboratories?
- Concentration
A few customers and products
Divi's top five customers gave 51% of FY26 standalone sales, up from 37% in FY24, and its top five products 48%. CARE said top-five product concentration above 60% could lead to a rating action.
Watch Top-five customer and product shares in the FY27 annual report.
- Demand
Lumpy custom work
Management said custom synthesis was 59% of sales in FY22, 44% in FY23, 45% in FY24 and 55% in FY26. Revenue fell 13.3% in FY23. Nilima Prasad Divi said on 1 Aug 2026: "as we always said, there is lumpiness".
Watch The custom synthesis share and revenue in each quarter.
- Cash and liquidity
Cash tied up in stock
Inventories rose from ₹3,954 crore to ₹5,540 crore between 31 Mar and 30 Sep 2026. H1 FY27 operating cash flow of ₹384 crore was below capital spending of ₹872 crore, and cash and bank balances fell to ₹2,236 crore.
Watch Inventories and operating cash flow in the FY27 results.
- Regulation
Regulator approvals for plants
Customers rely on plants passing inspections by the US FDA and others. A 2024 Unit 2 inspection ended with one procedural observation, and Unit 1's Nov 2025 inspection with none. Management said in Aug 2026 the US FDA may take 1 or 2 years to qualify Kakinada.
Watch US FDA inspection outcomes, filed with the exchanges.
- Currency
Currency moves
Exports were 89% of FY26 standalone sales, and 86% of exports were in US dollars. Forex gains in other income were ₹24 crore in Q2 FY27, against ₹63 crore in Q2 FY26.
Watch The rupee against the US dollar and the forex line in each results filing.
- Raw-material prices
Raw material and solvent costs
Imports were 44% of FY26 standalone materials. Nilima Prasad Divi said on 1 Aug 2026 that solvent costs rose, and that West Asia added uncertainty to supply chains.
Watch Materials as a share of revenue each quarter (32.1% in Q2 FY27).
- Legal
Tax disputes
A draft income-tax order proposes ₹570.51 crore of additions for AY 2023-24, with penalty proceedings for alleged under-reporting to be started separately. A GST demand totals ₹249 crore. Divi's says liability in both is remote.
Watch The Dispute Resolution Panel's decision and the Telangana High Court case.
- Execution
New capacity on time
Capital work in progress was ₹1,638 crore on 30 Sep 2026. The ₹650–700 crore dedicated facility was expected around Jan 2027, and new plants need customer and regulator validation before supply starts.
Watch Any filing on the start of the dedicated facility.
Sources (18)
- 36th Annual Report 2025-26 (FY26)
- 34th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated)
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- Earnings call transcript Q4 FY22 (call 23 May 2022)
- Earnings call transcript Q4 FY23 (call 20 May 2023)
- Earnings call transcript Q4 FY24 (call 25 May 2024)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- Consolidated financial results Q4 FY23 and FY23 (XBRL)
- Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Consolidated financial results Q2 FY27 (XBRL)
- US-FDA inspection of Unit-II (11–19 Jul 2024): one procedural observation
- US-FDA inspection of Unit-I (10–14 Nov 2025) concluded with no 483 observations
- Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release
- Draft assessment order under section 144C(1), Income Tax Act, AY 2023-24 (additions of ₹570.51 crore proposed)
- GST order on IGST refund (demand ₹82.04 crore plus equal penalty and interest)
- Information about proposed capacity addition (₹650–700 crore, long-term supply agreement)
08Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose from ₹7,845 crore in FY24 to ₹10,560 crore in FY26, and Q2 FY27 revenue of ₹3,676 crore was 35.4% above Q2 FY26.
- Divi's had no borrowings on 30 Sep 2026, and CARE rated its bank facilities AA+ (Stable) on 26 Aug 2025.
- Management said custom synthesis rose to 60% of standalone sales in Q1 FY27, and Divi's signed two long-term supply agreements in 2025.
- A US FDA inspection of Unit 1 in Nov 2025 ended with no Form 483 observations.
- No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
What critics point to
- Top five customers gave 51% of FY26 standalone sales, up from 37% in FY24, and top five products 48%.
- Inventories rose to ₹5,540 crore on 30 Sep 2026, and H1 FY27 operating cash flow of ₹384 crore was below capital spending of ₹872 crore.
- Revenue fell 13.3% in FY23, and net profit fell from ₹2,960 crore in FY22 to ₹1,600 crore in FY24.
- Divi's publishes no investor presentations, does not name its custom synthesis customers and gives its business mix only as rounded percentages in calls.
- The managing director was paid ₹100 crore in FY26, 1,692 times the median employee's pay.
09What to watch next
What should you watch next at Divi's Laboratories?
Next event
Q3 FY27 results
Date not announced yet.
Dedicated facility start
Divi's said in Apr 2024 the ₹650–700 crore facility was expected around Jan 2027; on 1 Aug 2026 Dr Kiran S. Divi said three major capex programmes were nearing completion, with validations going on.
Inventory and cash
Inventories were ₹5,540 crore and cash and bank balances ₹2,236 crore on 30 Sep 2026, against ₹3,954 crore and ₹3,414 crore on 31 Mar 2026.
Business mix
Whether a Q2 FY27 call is filed with the custom synthesis share; management said it was 60% of standalone sales in Q1 FY27.
10Key facts
Key facts about Divi's Laboratories
- What does Divi's Laboratories do?
- Divi's Laboratories Ltd is a Hyderabad company, incorporated in 1990, that makes active pharmaceutical ingredients (the chemicals in medicines that do the work), intermediates and nutraceutical ingredients. Divi's reported 3 manufacturing facilities and FY26 revenue from operations of ₹10,560 crore.
- How does Divi's Laboratories make money?
- Divi's Laboratories sells generic drug ingredients to medicine makers and makes ingredients under contract for drug innovators, which it calls custom synthesis. Divi's management said on its Q4 FY26 call (23 May 2026) that custom synthesis was 55% of FY26 sales and generics, including nutraceuticals, 45%; Divi's reports both as one segment.
- Who are Divi's Laboratories' customers?
- Divi's Laboratories sells mainly to drug companies outside India: in FY26 Europe gave 61.0% of Divi's revenue and the Americas 13.2% (Cityfort calculation from the FY26 annual report). Divi's top five customers gave 51% of FY26 standalone sales.
- How big is Divi's Laboratories?
- In FY26 Divi's Laboratories earned ₹10,560 crore of revenue and ₹2,568 crore of net profit, up from ₹9,360 crore and ₹2,191 crore in FY25. Divi's reported about 19,300 employees in its FY26 annual report.
- Who owns Divi's Laboratories?
- On 30 Sep 2026 the promoter group (Divi family members and Divi's Biotech) held 51.88% of Divi's Laboratories, with no shares pledged. Foreign investors held 20.38%, Indian institutions 19.17% and others, including individuals, 8.58%.
- How did Divi's Laboratories do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Divi's Laboratories' revenue was ₹3,676 crore, up 35.4% from ₹2,715 crore in Q2 FY26, and net profit was ₹1,127 crore, up 63.6% from ₹689 crore.
- Does Divi's Laboratories have debt?
- Divi's Laboratories had no borrowings on 30 Sep 2026 and ₹2,236 crore of cash and bank balances, down from ₹3,414 crore on 31 Mar 2026 (Cityfort calculation from the results filings). CARE rated Divi's bank facilities AA+ (Stable) on 26 Aug 2025.
- What dividend does Divi's Laboratories pay?
- Divi's Laboratories paid a dividend of ₹30 a share for each year from FY22 to FY26; the FY26 dividend came to ₹796 crore.
- Who runs Divi's Laboratories?
- Dr Murali K. Divi, the promoter, is managing director of Divi's Laboratories. Dr Kiran S. Divi is whole-time director and CEO, and Venkatesa Perumallu Pasumarthy has been chief financial officer since 1 Aug 2025.
Sources (15)
- 36th Annual Report 2025-26 (FY26)
- Business Responsibility and Sustainability Report 2025-26
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- Consolidated financial results Q4 FY25 and FY25 (XBRL)
- Shareholding pattern as of 30 Sep 2026 (XBRL)
- Consolidated financial results Q2 FY27 (XBRL)
- Consolidated financial results Q2 FY26 (XBRL)
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- 35th Annual Report 2024-25 (FY25)
- 34th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated)
- 33rd Annual Report 2022-23 (FY23; NSE zip)
- 32nd Annual Report 2021-22 (FY22; NSE zip)
- Board outcome 3 Feb 2025: re-appointment of Dr. Kiran S. Divi as Whole-time Director and CEO for 5 years
- Board outcome 17 May 2025: CFO L. Kishore Babu superannuates, Venkatesa Perumallu Pasumarthy appointed CFO
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Customer concentration
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
11What it sells
11What it sells
What does Divi's Laboratories sell?
Generic drug ingredients (APIs)
Active pharmaceutical ingredients (APIs), the chemicals in a medicine that do the work, for medicines whose patents have expired. CARE names naproxen (for arthritis pain), dextromethorphan, levodopa, gabapentin and nabumetone among them. Management said on its Q4 FY26 call (23 May 2026) that generics, including nutraceuticals, were 45% of FY26 sales.
Custom synthesis for drug innovators
Drug innovators hire Divi's to make APIs and intermediates (part-made ingredients) for their own medicines, from trials to commercial supply. Divi's says it is a partner to 12 of the top 20 pharmaceutical companies. Management said on its Q4 FY26 call (23 May 2026) that custom synthesis was 55% of FY26 sales.
Nutraceutical ingredients
Ingredients for human health, animal health and dietary supplements, with over 100 offerings, Dr Kiran S. Divi said in Aug 2026. Management said nutraceutical sales were ₹946 crore in FY26, about 9.0% of revenue (Cityfort calculation).
Peptides (new)
Building blocks and fragments for peptide medicines, chains of amino acids. Divi's set up a Peptide Centre of Excellence in FY26 and is adding solid- and liquid-phase peptide capacity.
What it does
- Does: Makes ingredients at 3 manufacturing facilities in Telangana and Andhra Pradesh
- Does: Sells mostly abroad: exports were 89% of FY26 standalone sales
- Does: Makes ingredients for drug innovators under confidentiality agreements
- Does: Signed two long-term supply agreements with global pharma companies in Apr and May 2025, for advanced intermediates
What it does not do
- Does not: Does not report selling finished medicines: its single reported segment is APIs, intermediates and nutraceutical ingredients
- Does not: Does not name its custom synthesis customers or products, citing confidentiality agreements
- Does not: Does not report profit by business: the generics and custom synthesis split is given only as rounded percentages in earnings calls
Sources (5)
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- 36th Annual Report 2025-26 (FY26)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
12How the money flows
12How the money flows · FY26
How does money flow through Divi's Laboratories?
Money in
- Revenue from operations₹10,560 cr
- Other income₹507 cr
The company
Divi's Laboratories
₹11,067 cr came in
Money out
- Materials₹4,093 cr
- Employee costs₹1,442 cr
- Other running costs₹1,584 cr
- Depreciation and interest₹486 cr
- One-off charge (employee benefits under the new labour codes)₹74 cr
- Income tax₹820 cr
- Net profit₹2,568 cr
- In FY26 Divi's sold ₹10,560 crore of ingredients and earned ₹507 crore of other income.
- Materials took ₹4,093 crore and employees ₹1,442 crore.
- Other running costs took ₹1,584 crore, and depreciation and interest ₹486 crore.
- A one-off labour-code charge took ₹74 crore and income tax ₹820 crore.
- What was left was ₹2,568 crore of net profit.
Sources (5)
13What it needs to run
13What it needs to run
What does Divi's Laboratories need to run?
Three manufacturing units
Unit 1 at Choutuppal, Telangana (from 1995), Unit 2 near Visakhapatnam, Andhra Pradesh (from 2003) and Unit 3 at Kakinada, Andhra Pradesh (from Jan 2025). Divi's gives its manufacturing capacity as ~18,600 M3/KL. Management said in Aug 2026 the units ran at around 85%.
Regulatory files
A drug master file (DMF) is a dossier on how an ingredient is made, filed with a regulator so customers can use it. In FY26 Divi's had 41 US DMFs, 30 European certificates (CEPs), 25 Health Canada DMFs and 9 Japanese files.
Raw materials
Materials took ₹4,093 crore in FY26, 38.8% of revenue. Imports were 44% of the materials Divi's used in FY26 (standalone).
People and research
About 19,300 employees and 4 R&D centres with about 700 scientists. R&D spending was ₹92 crore in FY26, 0.89% of sales.
Capital spending
Divi's spent ₹2,520 crore on plants and equipment in FY26 and ₹872 crore in H1 FY27. Work in progress not yet in use was ₹1,638 crore on 30 Sep 2026.
Sources (5)
- 36th Annual Report 2025-26 (FY26)
- Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Consolidated financial results Q2 FY27 (XBRL)
14Where it sells
14Where it sells · FY26
Where does Divi's Laboratories sell?
- Europe61%
- Americas13.2%
- India11%
- Rest of Asia10.2%
- Rest of the world4.5%
Sources (1)
15Where growth could come from
15Where growth could come from
Where could Divi's Laboratories' growth come from?
Management said on the Q4 FY26 call (23 May 2026) that "we always look for a double-digit growth in our revenues". It said margins would remain stable but did not give a figure. No Q2 FY27 call had been filed with NSE by 12 Nov 2026.
Custom synthesis
Working60% of standalone sales, Q1 FY27 (management)
Management said custom synthesis was 53% of sales in Q1 FY26, 55% in FY26 and 60% of standalone sales in Q1 FY27. Divi's does not report it as a separate segment.
Status: Working, on track against what the company said.
Dedicated capacity for long-term contracts
Early₹650–700 crore, 'around January, 2027'
Divi's said in Apr 2024 the facility for a long-term supply agreement was expected around Jan 2027. Divi's said on 24 May 2025 that capacity for its second 2025 agreement would cost an estimated ₹650–750 crore, funded from a capacity reservation advance the customer proposed to pay in phases. On 1 Aug 2026 Dr Kiran S. Divi said three major capex programmes were nearing completion, with validations going on.
Status: Early, too early to judge.
Unit 3 at Kakinada
Early₹600 crore of ₹1,500 crore capitalised (May 2026)
Commercial operations began from part of Phase I on 1 Jan 2025. Phase I covers 200 of the site's 500 acres, at an estimated ₹1,200–1,500 crore.
Status: Early, too early to judge.
Nutraceuticals
Working₹946 crore, FY26 (₹781 crore in FY25)
Management said nutraceutical sales were ₹298 crore in Q1 FY27, against ₹250 crore in Q1 FY26.
Status: Working, on track against what the company said.
Peptides
NewPeptide Centre of Excellence set up in FY26
Divi's is adding solid- and liquid-phase peptide synthesis capacity. Dr Kiran S. Divi said in Aug 2026 that validation of several peptide fragments should advance over the coming quarters.
Status: New, recently announced.
Generic ingredients
MixedVolumes stable, Q1 FY27 (management)
Dr Kiran S. Divi said on 1 Aug 2026 that generic volumes were stable while pricing reflected competitive market conditions.
Status: Mixed, partly on track.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (10)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
- Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release
- Earnings call transcript Q1 FY26 (call 6 Aug 2025)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Information about proposed capacity addition (₹650–700 crore, long-term supply agreement)
- Signing of long-term manufacturing and supply agreement with a global pharma company (advanced intermediates)
- Signing of a second long-term manufacturing and supply agreement with a global pharma company (advanced intermediates)
- Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025)
- Earnings call transcript Q4 FY25 (call 17 May 2025)
- 36th Annual Report 2025-26 (FY26)
16Financial strength and debt
16Financial strength · 30 Sep 2026
How much debt does Divi's Laboratories have?
- Total debt₹0 cr
- Cash and investments₹2,236 cr
- Net cash (cash minus debt)₹2,236 cr
- Net worth (shareholders' money)₹17,997 cr
- Debt to equity
- 0×
- ₹ of debt for every ₹1 of shareholders' money
- In H1 FY27 operating cash flow was ₹384 crore (₹1,645 crore in H1 FY26), against ₹872 crore spent on plants and equipment and ₹797 crore of dividends paid.
- Inventories rose from ₹3,954 crore on 31 Mar 2026 to ₹5,540 crore on 30 Sep 2026, and trade receivables from ₹2,984 crore to ₹3,487 crore. Nilima Prasad Divi said on 1 Aug 2026 that Divi's kept strategic inventory buffers given supply risks linked to West Asia.
- Cash and bank balances = cash and equivalents plus other bank balances; Divi's held no current investments. Management said on the Q4 FY26 call (23 May 2026) that cash and cash equivalents stood at ₹3,414 crore on 31 Mar 2026, the same as our figure.
- A ₹456 crore refundable advance from a customer (31 Mar 2026) is not counted as borrowing. Lease liabilities were ₹7 crore on 31 Mar 2026.
Sources (6)
- Consolidated financial results Q2 FY27 (XBRL)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Consolidated financial results Q2 FY26 (XBRL)
- 36th Annual Report 2025-26 (FY26)
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Earnings call transcript Q4 FY26 (call 23 May 2026)
17Who owns it
17Who owns it · Q2 FY27
Who owns Divi's Laboratories?
- Promoters (founders or parent company)51.9%
- Foreign institutions (FII)20.4%
- Indian institutions (DII)19.2%
- Public and others8.6%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (12)
- Shareholding pattern as of 31 Dec 2023 (XBRL)
- Shareholding pattern as of 31 Mar 2024 (revised filing 4 Jun 2024) (XBRL)
- Shareholding pattern as of 30 Jun 2024 (XBRL)
- Shareholding pattern as of 30 Sep 2024 (revised filing 7 Nov 2024) (XBRL)
- Shareholding pattern as of 31 Dec 2024 (XBRL)
- Shareholding pattern as of 31 Mar 2025 (XBRL)
- Shareholding pattern as of 30 Jun 2025 (XBRL)
- Shareholding pattern as of 30 Sep 2025 (XBRL)
- Shareholding pattern as of 31 Dec 2025 (XBRL)
- Shareholding pattern as of 31 Mar 2026 (XBRL)
- Shareholding pattern as of 30 Jun 2026 (XBRL)
- Shareholding pattern as of 30 Sep 2026 (XBRL)
18What it does with profit
18What it does with profit
What does Divi's Laboratories do with its profit?
Dividend per share
₹30.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
No buybacks or fund raises in the period covered.
Sources (10)
- 32nd Annual Report 2021-22 (FY22; NSE zip)
- Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL)
- 33rd Annual Report 2022-23 (FY23; NSE zip)
- Consolidated financial results Q4 FY23 and FY23 (XBRL)
- 34th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated)
- Consolidated financial results Q4 FY24 and FY24 (XBRL)
- 35th Annual Report 2024-25 (FY25)
- Consolidated financial results Q4 FY25 and FY25 (XBRL)
- 36th Annual Report 2025-26 (FY26)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
19Governance signals
19Governance signals
What do Divi's Laboratories' governance filings show?
- Auditor
- Price Waterhouse Chartered Accountants LLP
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- In FY26 Divi's bought ₹50 crore from firms in which relatives of key managers have an interest, up from ₹34 crore in FY25. They were Sri Lakshmi Constructions (₹43 crore) and Bheema Infra Solutions (₹7 crore). It pays lease rent to promoter-controlled Divi's Properties and Divi's Biotech. Standalone figures from the FY26 annual report.
- Credit rating
- CARE Ratings CARE AA+ (Stable) on ₹30 crore of long-term bank facilities, and CARE AA+ (Stable) / CARE A1+ on ₹485 crore of long/short-term facilities: ₹515 crore in all (outlook Stable), 26 Aug 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
disclosure · 12 Nov 2026
No investor presentations; business mix only in calls
Divi's publishes no investor presentations and reports one business segment. Its generics and custom synthesis split comes only as rounded percentages in earnings calls. No Q2 FY27 call had been filed with NSE by 12 Nov 2026.
other · 15 Jul 2026
Pay of the managing director
Dr Murali K. Divi, managing director and promoter, was paid ₹100 crore in FY26 (₹88 crore in FY25), 1,692 times the median employee's pay. Pay to key managers totalled ₹224 crore, 2.1% of revenue (Cityfort calculation).
other · 16 Apr 2026
Income-tax and GST disputes
An income-tax draft order of 20 Mar 2026 proposed additions of ₹570.51 crore for AY 2023-24, on transfer-pricing and corporate tax adjustments; Divi's filed objections on 16 Apr 2026. A GST order of 31 Oct 2023 demands ₹249 crore: ₹82 crore of IGST refunds the tax office alleges were claimed in error, plus an equal penalty and interest. The Telangana High Court has stayed collection. Divi's says liability in both is remote.
regulatory · 19 Nov 2024
FEMA penalty for late reports
The Directorate of Enforcement, Hyderabad, levied a penalty of ₹6 lakh (₹0.06 crore) each on Divi's and its CEO under FEMA, by an order of 19 Nov 2024. The reason given was procedural delay in filing annual performance reports on its overseas subsidiaries for 2005-06 to 2010-11, 2013-14 and 2014-15.
Sources (9)
- 36th Annual Report 2025-26 (FY26)
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- Intimation of reaffirmation of credit rating by CARE (13 Sep 2024)
- Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release
- Earnings call transcript Q1 FY27 (call 1 Aug 2026)
- Draft assessment order under section 144C(1), Income Tax Act, AY 2023-24 (additions of ₹570.51 crore proposed)
- GST order on IGST refund (demand ₹82.04 crore plus equal penalty and interest)
- Update on GST order: writ petition filed, interim order (10% deposit, no coercive action)
- Enforcement Directorate order: FEMA penalty of ₹6 lakh each on the company and its CEO (late Annual Performance Reports)
20What the market paid
20What the market paid · price as of 11 Nov 2026
What did the market pay for Divi's Laboratories on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹11,367.00, the NSE closing price. Market value = price × 265,468,580 shares = ₹301,758 crore (Cityfort calculation). P/E (price ÷ earnings per share) = price ÷ earnings per share of the last four quarters (Q3 FY26 to Q2 FY27, ₹126.73) = 89.7. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹17,997 crore) = 16.8. Dividend yield = FY26 dividend of ₹30 ÷ price = 0.26%.
- Share price
- ₹11,367.00
- Market value (market cap)
- ₹301,758 cr
- P/E
- 89.7×
- P/B
- 16.8×
Source: NSE equity bhavcopy, 11 Nov 2026 (DIVISLAB close); Shareholding pattern as of 30 Sep 2026 (XBRL); Consolidated financial results Q3 FY26 (XBRL) and 4 more
Sources (7)
- NSE equity bhavcopy, 11 Nov 2026 (DIVISLAB close)
- Shareholding pattern as of 30 Sep 2026 (XBRL)
- Consolidated financial results Q3 FY26 (XBRL)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
- Consolidated financial results Q1 FY27 (XBRL)
- Consolidated financial results Q2 FY27 (XBRL)
- 36th Annual Report 2025-26 (FY26)
21How it got here
21How it got here
How did Divi's Laboratories get here?
1990
Milestone
Incorporated
Divi's Laboratories was incorporated in Hyderabad in Oct 1990, promoted by Dr Murali K. Divi.
1995
Milestone
First plant
Unit 1 at Lingojigudem, Choutuppal, Telangana began operations in 1995.
2003
Milestone
Export plant near Visakhapatnam
Unit 2 at Chippada, near Visakhapatnam, started as an export-oriented unit in 2003, later in special economic zones.
2021
Milestone
Molnupiravir API
In May 2021 Divi's said it was MSD's authorised maker of the molnupiravir API, allowed to supply MSD's licence partners in India.
2023
Crisis
Revenue and profit fell
FY23 revenue fell 13.3% to ₹7,768 crore and net profit 38.4% to ₹1,823 crore. Standalone North America sales fell from ₹3,833 crore in FY22 to ₹1,310 crore in FY24.
2024
Business-model change
Dedicated capacity for one customer
In Apr 2024 Divi's said it would invest ₹650–700 crore in capacity for a long-term supply agreement with a customer.
2025
Milestone
Unit 3 at Kakinada
Commercial operations began from part of Phase I of the Kakinada plant on 1 Jan 2025.
2025
Business-model change
Two long-term supply agreements
In Apr and May 2025 Divi's signed long-term agreements with global pharma companies to make advanced intermediates.
2026
Milestone
Peptide centre and ₹10,560 crore revenue
FY26 revenue reached ₹10,560 crore, the highest of the five years, and Divi's set up a Peptide Centre of Excellence.
Sources (11)
- Business Responsibility and Sustainability Report 2025-26
- CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+)
- 36th Annual Report 2025-26 (FY26)
- Intimation about manufacturing of Molnupiravir API (MSD authorised manufacturer)
- Consolidated financial results Q4 FY23 and FY23 (XBRL)
- Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL)
- Information about proposed capacity addition (₹650–700 crore, long-term supply agreement)
- Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025)
- Signing of long-term manufacturing and supply agreement with a global pharma company (advanced intermediates)
- Signing of a second long-term manufacturing and supply agreement with a global pharma company (advanced intermediates)
- Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL)
22Sources and changes
Where every number on this page comes from
Sources (57 documents)
- S136th Annual Report 2025-26 (FY26) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 15 Jul 2026
- S235th Annual Report 2024-25 (FY25) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Jul 2025
- S334th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated) · Divi's Laboratories Ltd · Tier 1: company or exchange filing · 15 Jul 2024
- S433rd Annual Report 2022-23 (FY23; NSE zip) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 2 Aug 2023
- S532nd Annual Report 2021-22 (FY22; NSE zip) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 Jul 2022
- S6Consolidated financial results Q2 FY27 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Nov 2026
- S7Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Nov 2026
- S8Consolidated financial results Q1 FY27 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 1 Aug 2026
- S9Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 May 2026
- S10Consolidated financial results Q3 FY26 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Feb 2026
- S11Consolidated financial results Q2 FY26 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Nov 2025
- S12Consolidated financial results Q1 FY26 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 6 Aug 2025
- S13Consolidated financial results Q4 FY25 and FY25 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 May 2025
- S14Consolidated financial results Q3 FY25 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 3 Feb 2025
- S15Consolidated financial results Q4 FY24 and FY24 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 May 2024
- S16Consolidated financial results Q4 FY23 and FY23 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 20 May 2023
- S17Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 May 2022
- S18Earnings call transcript Q1 FY27 (call 1 Aug 2026) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 6 Aug 2026
- S19Earnings call transcript Q4 FY26 (call 23 May 2026) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 May 2026
- S20Earnings call transcript Q3 FY26 (call 11 Feb 2026) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Feb 2026
- S21Earnings call transcript Q2 FY26 (call 7 Nov 2025) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Nov 2025
- S22Earnings call transcript Q1 FY26 (call 6 Aug 2025) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Aug 2025
- S23Earnings call transcript Q4 FY25 (call 17 May 2025) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 May 2025
- S25Earnings call transcript Q4 FY24 (call 25 May 2024) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 May 2024
- S26Earnings call transcript Q4 FY23 (call 20 May 2023) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 May 2023
- S27Earnings call transcript Q4 FY22 (call 23 May 2022) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 May 2022
- S28Shareholding pattern as of 30 Sep 2026 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 6 Oct 2026
- S29Shareholding pattern as of 30 Jun 2026 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 Jul 2026
- S30Shareholding pattern as of 31 Mar 2026 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 15 Apr 2026
- S31Shareholding pattern as of 31 Dec 2025 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Jan 2026
- S32Shareholding pattern as of 30 Sep 2025 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 Oct 2025
- S33Shareholding pattern as of 30 Jun 2025 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Jul 2025
- S34Shareholding pattern as of 31 Mar 2025 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Apr 2025
- S35Shareholding pattern as of 31 Dec 2024 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 Jan 2025
- S36Shareholding pattern as of 30 Sep 2024 (revised filing 7 Nov 2024) (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Nov 2024
- S37Shareholding pattern as of 30 Jun 2024 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Jul 2024
- S38Shareholding pattern as of 31 Mar 2024 (revised filing 4 Jun 2024) (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Jun 2024
- S39Shareholding pattern as of 31 Dec 2023 (XBRL) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Jan 2024
- S40CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+) · CARE Ratings Ltd · Tier 2: rating agency or regulator · 26 Aug 2025
- S41Intimation of reaffirmation of credit rating by CARE (13 Sep 2024) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Sep 2024
- S42Business Responsibility and Sustainability Report 2025-26 · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 15 Jul 2026
- S43NSE equity bhavcopy, 11 Nov 2026 (DIVISLAB close) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
- S44Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 2 Jan 2025
- S45Information about proposed capacity addition (₹650–700 crore, long-term supply agreement) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 Apr 2024
- S46Signing of long-term manufacturing and supply agreement with a global pharma company (advanced intermediates) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Apr 2025
- S47Signing of a second long-term manufacturing and supply agreement with a global pharma company (advanced intermediates) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 24 May 2025
- S48US-FDA inspection of Unit-I (10–14 Nov 2025) concluded with no 483 observations · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Nov 2025
- S49US-FDA inspection of Unit-II (11–19 Jul 2024): one procedural observation · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Jul 2024
- S50Draft assessment order under section 144C(1), Income Tax Act, AY 2023-24 (additions of ₹570.51 crore proposed) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 21 Mar 2026
- S51GST order on IGST refund (demand ₹82.04 crore plus equal penalty and interest) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Nov 2023
- S52Update on GST order: writ petition filed, interim order (10% deposit, no coercive action) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 3 Jan 2024
- S53Enforcement Directorate order: FEMA penalty of ₹6 lakh each on the company and its CEO (late Annual Performance Reports) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Dec 2024
- S54Clarification on news item (US court ruling on a Novartis generic): company supplies under agreements and cannot comment · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 5 Dec 2024
- S55Board outcome 17 May 2025: CFO L. Kishore Babu superannuates, Venkatesa Perumallu Pasumarthy appointed CFO · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 May 2025
- S56Board outcome 3 Feb 2025: re-appointment of Dr. Kiran S. Divi as Whole-time Director and CEO for 5 years · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 3 Feb 2025
- S57Board outcome 7 Nov 2025: N.V. Anirudh designated President (Nutraceuticals), senior management · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 7 Nov 2025
- S60Intimation about manufacturing of Molnupiravir API (MSD authorised manufacturer) · Divi's Laboratories Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 May 2021
Changes to this page (v1 · 12 Nov 2026)
- v1 · 12 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.